Integrated BioPharma (OTCMKTS:INBP – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Analyst Ratings
This is a summary of current recommendations and price targets for Integrated BioPharma and Ernexa Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integrated BioPharma | 0 | 0 | 0 | 0 | 0.00 |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 409.34%. Given Ernexa Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Integrated BioPharma.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integrated BioPharma | $54.35 million | 0.11 | $810,000.00 | ($0.07) | -2.71 |
| Ernexa Therapeutics | $580,000.00 | 11.88 | -$14.08 million | ($26.20) | -0.22 |
Integrated BioPharma has higher revenue and earnings than Ernexa Therapeutics. Integrated BioPharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
25.3% of Integrated BioPharma shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 67.4% of Integrated BioPharma shares are held by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Integrated BioPharma has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500.
Profitability
This table compares Integrated BioPharma and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integrated BioPharma | -3.43% | -8.32% | -6.57% |
| Ernexa Therapeutics | N/A | -263.74% | -151.16% |
Summary
Ernexa Therapeutics beats Integrated BioPharma on 8 of the 14 factors compared between the two stocks.
About Integrated BioPharma
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
